US FDA and ARPA-H: Woodcock Has Questions
Executive Summary
The FDA’s principal deputy commissioner wonders how the agency will work with ARPA-H to help get its projects to patients and the health care system given its other responsibilities.
You may also be interested in...
ARPA-H, US FDA Discuss Incentives For Game-Changing Health Projects
Because the Advanced Research Projects Agency for Health can reimburse FDA for services, the two agencies are discussing what that could be available, such as priority assessments, when the projects reach the application stage.
Inter-Agency User Fees? US FDA/ARPA-H Relationship Could Get Interesting
The Biden Administration’s signature health research agency ARPA-H is still in the formative stages. Authorizing legislation moving through Congress could set up a very interesting dynamic when it comes to working with the US FDA.
House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval
Clinical trial diversity, FDA hiring authority, and inactive ingredient disclosure provisions all get slight modifications. The bill glides through committee, but not without some complaints about agency performance.